Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland. It was founded in 2003.[2] One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales.[1] In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA).
Public | |
Traded as | NASDAQ: JAZZ Russell 1000 Index component |
Industry | Biotechnology Pharmaceutical |
Predecessor | Jazz Pharmaceuticals, Inc. (before the 2012 tax inversion to Ireland) |
Founded | March 2005 in Dublin, Ireland |
Headquarters | Waterloo Exchange, Waterloo Road, D04 E5W7, Dublin, Ireland |
Area served | Worldwide |
Key people | Bruce C. Cozadd, Chairman & CEO |
Products | Pharmaceutical drugs |
Brands | |
Revenue | |
Total assets | |
Total equity | |
Number of employees | ~1,210 (February 2018)[1] |
Website | www |
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.[3]
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[4]
Company history & Acquisitions
2010
On February 18, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia.[5] In the following December, a new patent was issued for Sodium Oxybate.[6]
2011
On September 19, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge.[7]
2012
On April 26, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments).[8] In September the company successfully sold its Women's Health business to Meda for $95 million.[9] In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia.[10]
2014
In January, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.[11][12]
2016
In May, the company announced it would acquire Alizé Pharma II for $20.5 million.[13] At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.[14] As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.[15]
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Jazz Pharmaceuticals |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- "Jazz Pharmaceuticals PLC 2017 Annual Report (Form 10-K)". sec.gov. U.S. Securities and Exchange Commission. February 2018.
- "History". Jazz Pharmaceuticals. Retrieved 22 November 2016.
- "Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in "Off-label" Marketing Investigation".
- http://www.fiercepharma.com/pharma/teva-wins-controversial-phrma-bid-despite-protests-from-branded-rivals
- "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
- Armstrong, Drew (December 19, 2013). "Jazz to Buy Gentium for $1 Billion for Rare-Disease Drugs". Bloomberg News.
- "Jazz Pharma Acquiring Gentium for $1B". Gen. Eng. Biotechnol. News (paper)
|format=
requires|url=
(help). 34 (2). January 15, 2014. p. 10. - "Alizé Pharma II Acquired by Jazz Pharmaceuticals for Up to $20.5M - GEN News Highlights - GEN".
- "Jazz Pharmaceuticals to Acquire Celator for $1.5B - GEN News Highlights - GEN".
- "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Retrieved 2018-12-30.
- https://www.biospace.com/article/releases/jazz-pharmaceuticals-announces-acquisition-of-cavion-inc-/?s=79
- https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-acquisition-cavion-inc